freeze-thaw is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-11. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
If R1 is the inner cylinder radii and R2 is the outer cylinder radii, with constant applied pressure gradient between the two ends G = −dp/dx, the velocity distribution and the volume flux through the annular pipe are
He was a consistent performer in an inconsistent season for the Bombers, polling 16 Brownlow votes from a total of 43 received by Essendon players, including a three-vote game in his 100th AFL game, finishing equal-seventh in the 2010 Brownlow Medal count, and having the highest number of votes for a player from a team finishing outside the final eight. Watson was once again awarded the Crichton Medal, earning 291 points, which was 50 points clear of runner-up Heath Hocking. Watson had a relatively good season in 2011 despite missing six weeks with a hamstring injury, earning 15 Brownlow votes and finishing runner-up in the Crichton Medal, losing out to up-and-coming third-year midfielder David Zaharakis. Watson completed an outstanding 2012 season by winning the Brownlow Medal with 30 votes (though he was later ruled ineligible after being suspended during the Essendon Football Club supplements saga). Along with his third Crichton Medal, he also won a handful of other accolades, including the AFLPA best captain award, the Lou Richards Medal and selection in the 2012 All-Australian team as the centreman. Watson missed three weeks with a broken collarbone in 2013, but had another consistent season, earning 17 Brownlow votes, finishing runner-up in the Crichton Medal to former St Kilda utility (and later successor as captain) Brendon Goddard, and being named on the interchange in the 2013 All-Australian team. Between 2006 and 2013, Watson finished all but one season in the top two for votes for the Crichton Medal.
== History of space medicine and drug delivery == Concerns about aviation drug delivery started as early as 1924 when orthostatic stress was found to be the reason for a pilot's inability to digest chocolate during a flight. In addition, studies on the effect of digitalis on altitude were performed on both pigeons and cats in 1924, concluding that increased altitudes significantly increase the effects of digitalis on their systems, leading to a recommendation to decrease the dosage of digitalis in high altitudes to be two-fifths of the current dose. As outer space expeditions grew in the mid-twentieth century, missions established medical practices to deliver medicines for astronauts in missions. Project Apollo in the late 1960s to early 1970s began the use of using medicine bags, which came with commonly used drugs for motion sickness and pain relief in oral form (tablets and capsules) as well as a nasal spray. The Mercury Project was one of the first space expeditions to take medicine delivery to outer space. Injector systems were first developed and used then to deliver and inject drugs directly into an individual's spacesuit into their thighs. These injection tubes were used to deliver Tigan and Demerol, respectively, motion sickness and pain relief drugs. Studies in the 1980s examined common orally-delivered drug functionalities in altered space environments, beginning with acetaminophen, concluding that they were less effective in outer space.
In 1994 560 grams of plutonium and uranium oxide were intercepted at Munich airport in an airplane coming from Moscow. The precise composition was 363 grams plutonium (87% of which was Plutonium-239) and 122 grams of uranium. It later emerged through a German parliamentary enquiry that the purchase had been arranged and financed by the German Federal Intelligence Service. U.S. Department of Energy official Jay A. Tilden has advocated for the use of nuclear forensics science to assign responsibility for, or resolve ambiguity about, "unattributed nuclear events," such as accidents at nuclear facilities, nuclear weapons mishaps in denied geographic areas, accidental nuclear detonations, the limited use of nuclear weapons and subsequent denial of responsibility by the perpetrator, and attempts to blame a clandestine nuclear attack on non-state actors. An example of an unattributed nuclear event was the September 2017 unattributed release of the radioisotope ruthenium across central and eastern Europe and Asia.
=== Discovery === Ritonavir (initially designated as ABT-538) was developed through the systematic structural modification of A-80987, a moderately potent, symmetry-based HIV protease inhibitor. While A-80987 demonstrated good oral bioavailability, its clinical utility was limited by a very short circulating half-life. This rapid clearance was primarily driven by the oxidative metabolism (specifically N-oxidation) of its pyridyl end groups by cytochrome P450 enzymes in the liver and intestine.
Sources: en.wikipedia.org
As of July 2024, lisdexamfetamine is the only pharmacotherapy approved by the US Food and Drug Administration (FDA) and the Therapeutic Goods Administration for BED. Evidence indicates that its effectiveness in treating BED may be partially due to a psychopathological overlap with attention deficit hyperactivity disorder, a cognitive-control disorder that also benefits from treatment with lisdexamfetamine. Medical reviews of randomized controlled trials have established that lisdexamfetamine, administered at doses between 50 and 70 mg, is safe and effective for treating BED. These reviews consistently report fewer weekly binge eating episodes. Furthermore, a meta-analytic systematic review included a 12-month study showing the medication was effective for a long period of time. Two reviews have found lisdexamfetamine to be superior to placebo in several secondary outcomes, including persistent binge eating cessation and reductions in obsessive-compulsive binge eating symptoms, body weight, and triglycerides. Lisdexamfetamine is a pharmacologically inert prodrug that confers its therapeutic effects for BED after conversion to its active metabolite, dextroamphetamine, which acts in the central nervous system. Dextroamphetamine increases the availability of dopamine and norepinephrine in the prefrontal cortex, which makes major decision-making for the body. Lisdexamfetamine, like all pharmaceutical amphetamines, possesses direct appetite suppressant effects, which may be therapeutically beneficial for BED and its associated comorbidities.
== Radiolabeled somatostatin receptor antagonists in Peptide Radionuclide Receptor Therapy (PRRT) == Somatostatin receptor antagonists are also being developed as therapeutic agents in peptide radionuclide receptor therapy (PRRT) due to the wider binding of antagonists compared to agonists. Research indicated the antagonist Lu-DOTA-JR11 showed a higher tumor uptake, more double-strand breaks within tumor cells, longer adherence time to tumors and improved tumor-to-kidney dose ratio. Moreover, another study finds out the radionuclide terbium-161, which can release short-ranged electrons, can combine with somatostatin receptor antagonists that localize at the cell membrane. acting as an alternative to the current clinically used lutetium-somatostatin receptor agonist, which are localized at the cytoplasm and nucleus. Moreover, Tb-antagonist in vitro shows 102-fold higher potency than Lu-antagonists in inhibiting tumor cell growth and survival prolongation in mice, due to its high linear energy transfer. This result is further repeated and confirmed in vivo, showing the high potential and strengths of radiolabeled somatostatin receptor antagonists to treat neuroendocrine neoplasms.
Korolev's design bureau produced two prospectuses for circumlunar spaceflight (March 1962 and May 1963), the main spacecraft for which were early versions of his Soyuz design. At the same time, another bureau, OKB-52, headed by Vladimir Chelomey, was developing the LK-1 lunar flyby spacecraft, which would be launched by Chelomey's Proton UR-500 rocket. The Soviet government rejected Korolev's proposals, opting to support Chelomey's project, who gained favor with Khrushchev by employing his son. Officially, the Soviet lunar program was established on August 3, 1964, with the adoption of Soviet Communist Party Central Committee Command 655-268 (On Work on the Exploration of the Moon and Mastery of Space). The circumlunar flights were planned to occur in 1967, and the landings to start in 1968, intending to land a person on the Moon before the Apollo flights. Both of the bureaus submitted their projects for a crewed lunar landing. Korolev's lunar landing program was designated N1/L3, for its N1 super rocket and a more advanced Soyuz 7K-L3 spacecraft, also known as the lunar orbital module ("Lunniy Orbitalny Korabl", LOK), with a crew of two. A separate lunar lander ("Lunniy Korabl", LK), would carry a single cosmonaut to the lunar surface. The N1/L3 launch vehicle had three stages to Earth orbit, a fourth stage for Earth departure, and a fifth stage for lunar landing assist. The combined space vehicle was roughly the same height and takeoff mass as the three-stage US Apollo-Saturn V and exceeded its takeoff thrust by 28% (45,400 kN vs. 33,000 kN.
joint involvement, designating the metacarpophalangeal joints, proximal interphalangeal joints, the interphalangeal joint of the thumb, second through fifth metatarsophalangeal joint and wrist as small joints, and shoulders, elbows, hip joints, knees, and ankles as large joints: Involvement of 1 large joint gives 0 points Involvement of 2–10 large joints gives 1 point Involvement of 1–3 small joints (with or without involvement of large joints) gives 2 points Involvement of 4–10 small joints (with or without involvement of large joints) gives 3 points Involvement of more than 10 joints (with involvement of at least 1 small joint) gives 5 points serological parameters – including the rheumatoid factor as well as ACPA – "ACPA" stands for "anti-citrullinated protein antibody": Negative RF and negative ACPA gives 0 points Low-positive RF or low-positive ACPA gives 2 points High-positive RF or high-positive ACPA gives 3 points acute phase reactants: 1 point for elevated erythrocyte sedimentation rate, ESR, or elevated CRP value (c-reactive protein) duration of arthritis: 1 point for symptoms lasting six weeks or longer The new criteria incorporate the growing understanding of and the advances in diagnosing and treating RA. In the "new" criteria, serology and autoimmune diagnostics carry major weight, as ACPA detection is appropriate to diagnose the disease in an early state, before joints destructions occur. Destruction of the joints seen in radiological images was a significant point in the ACR criteria from 1987.
=== Mass spectrometry analysis === Mass spectrometry is currently the best method to adequately compare pairs of protein samples. The two main procedures to perform this task are using isotope-coded affinity tags (ICAT) and stable isotopic amino acids in cell culture (SILAC). In the ICAT procedure samples are labeled individually after isolation with mass-coded reagents that modify cysteine residues. In SILAC, cells are cultured separately in the presence of different isotopically labeled amino acids for several cell divisions allowing cellular proteins to incorporate the label. Mass spectrometry is subsequently used to identify phosphoserine, phosphothreonine, and phosphotyrosine-containing peptides.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.